International Journal of Cardiology The role of cystatin C as a biomarker for prognosis in pulmonary arterial hypertension due to congenital heart disease Ilja M. Blok, Annelieke C.M.J. van Riel, Mark J. Schuuring, Rianne H.A.C.M. de Bruin-Bon, Arie P.J. van Dijk, Elke S. Hoendermis, Aeilko H. Zwinderman, Barbara J.M. Mulder, Berto J. Bouma International Journal of Cardiology Volume 209, Pages 242-247 (April 2016) DOI: 10.1016/j.ijcard.2016.02.003 Copyright © 2016 The Authors Terms and Conditions
Fig. 1 Univariate predictors of outcome. To improve reader convenience all predictors with a protecting effect on survival were multiplied with minus one. Thus an increase of a predictor's value equals a worse prognosis. International Journal of Cardiology 2016 209, 242-247DOI: (10.1016/j.ijcard.2016.02.003) Copyright © 2016 The Authors Terms and Conditions
Fig. 2 Kaplan Meijer cystatin C above 1.10mg/l. International Journal of Cardiology 2016 209, 242-247DOI: (10.1016/j.ijcard.2016.02.003) Copyright © 2016 The Authors Terms and Conditions
Fig. 3 Predicted survival model based on cystatin C and NT-pro-BNP serum levels. CysC=cystatin C. International Journal of Cardiology 2016 209, 242-247DOI: (10.1016/j.ijcard.2016.02.003) Copyright © 2016 The Authors Terms and Conditions